Dr Rifat Hamoudi awarded funding from the St Peters Trust/Royal Free Charity grant to investigate post-therapeutic immune response in Prostate Cancer
10 August 2016
There are several new approaches to minimally invasive treatment of prostate cancer involving the local application of energy such as light or ultrasound but relatively little is known about whether the treatment can stimulate an immune response which could reduce the chance of metastatic spread and improve patient survival.
Dr Rifat Hamoudi designed a pilot proposal with the aim to carry out an investigation in a translational model of prostate cancer subjected to minimally invasive treatment with light-activatable agents to determine the role of the immune response. The results of this pilot project will be of generic relevance to other energy-directed therapies and can provide insights into the mechanism of prostate cancer resistance towards chemotherapuetic treatments and thus can have wide ranging impact on prostate cancer therapy.
The work will be carried out with Professor Alexander MacRobert, who has extensive expertise in photochemistry and photobiology and their application to experimental and translational studies and Ms Caroline Moore, who is a clinical academic urologist at UCL/UCLH specialising in the use of imaging in the prostate cancer pathway, including the use of minimally invasive therapies for the focal treatment of localised prostate cancer.
Dr. Rifat Hamoudi has extensive experience in immunopathology, molecular pathology and bioinformatics and their application to deciphering the molecular mechanism of disease.